Log In Sign Up

Trading

Trading

Browse Companies

Data

Data

Private Market Index

IPO Stock Tracker

Solutions

Solutions

For Institutions

For Shareholders

Insights

Insights

Popular Topics

Buying Pre-IPO Shares

Selling Pre-IPO Shares

Private Market Reports

Private Market Data & Analytics

About

About

Investor Relations

People & Culture

Prelude Therapeutics Stock

preludetx.comHealthcareFounded: 2016Funding to Date: $95MM

Prelude Therapeutics is a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.

Learn more about Prelude Therapeutics IPO

Overview Financings Valuation

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Prelude Therapeutics.

Register Today

Team

Management Team

Krishna Vaddi Ph.D

Founder, Chief Executive Officer & Board Member

David Mauro Ph.D

Chief Medical Officer

Peggy Scherle Ph.D

Chief Scientific Officer

Board Members

Krishna Vaddi Ph.D

Paul Friedman

Kelvin Neu

David Bonita

Other companies like Prelude Therapeutics in the Healthcare sector

Sector

Last Round Est. Valuation

$3.67B

Sector

Last Round Est. Valuation

$809.52MM

Colossal Biosciences

Sector

Last Round Est. Valuation

$1.01B

Sector

Sector

Last Round Est. Valuation

$4.26B

Sector

Sector

Last Round Est. Valuation

$396.01MM

Sector

Last Round Est. Valuation

$400.53MM

Sector

Last Round Est. Valuation

$1.53B

News

Pulse 2.0 06/19/2019

Prelude Therapeutics Closes $60 Million To Develop Drugs Targeting Drivers Of Cancer Cell Growth

Wilmington, Delaware-based clinical-stage biopharmaceutical company Prelude Therapeutics has raised $60 million in funding

Frequently Asked Questions